sotigalimab
apexigen
['esophageal', 'sotigalimab', 'gastroesophageal', 'apexigen']
apexigen presents new data from a phase 2 trial evaluating its cd40 antibody, sotigalimab, in combination with neoadjuvant chemoradiation in patients with resectable esophageal and gastroesophageal junction cancers at esmo congress 2022 
We provide a balanced view on small cap biotech equities.